Literature DB >> 3484981

Immune phagocytosis inhibition by commercial immunoglobulins.

J Neppert, M Clemens, C Mueller-Eckhardt.   

Abstract

Sixteen commercially available immunoglobulins (Ig) and 5 anti-Rho (D) hyperimmune globulins were investigated for immune phagocytosis inhibition (IPI) factors as well as for T, B lymphocytotoxic and monocytotoxic antibodies. All Ig contained IPI factors with lowest inhibitory IgG concentrations ranging from 0.08 to 50 mg/ml. Pepsin-digested Ig was noninhibitory. IPI factors in anti-D preparations were uniformly high (inhibitory IgG concentrations 0.6-2.5 mg/ml). Cytotoxic antibodies against T, B lymphocytes and monocytes were found in 2,2 and 7 products, respectively. Since we have recently shown that IPI is caused by antibodies against major histocompatibility complex antigens, most likely HLA, the hypothesis is put forward that IPI factors in Ig are HLA-related, cytotoxic as well as noncytotoxic antibodies which act via Fc receptor blockade of human monocytes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484981     DOI: 10.1007/BF00321069

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  20 in total

1.  Improved B cell typing for HLA-DR using nylon wool column enriched B lymphocyte preparations.

Authors:  R Lowry; J Goguen; C B Carpenter; T B Strom; M R Garovoy
Journal:  Tissue Antigens       Date:  1979-10

2.  Anti-Ia-like antibodies: preliminary use in rheumatoid arthritis.

Authors:  J Clot; J Sany
Journal:  Immunol Today       Date:  1984-05

3.  Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia.

Authors:  A Salama; V Kiefel; C Mueller-Eckhardt
Journal:  Am J Hematol       Date:  1986-07       Impact factor: 10.047

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin.

Authors:  G Berlin; A Selbing; G Ryden
Journal:  Lancet       Date:  1985-05-18       Impact factor: 79.321

Review 6.  Clinical use of immunoglobulins.

Authors:  D B McClelland; P L Yap
Journal:  Clin Haematol       Date:  1984-02

7.  Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D).

Authors:  A Salama; V Kiefel; R Amberg; C Mueller-Eckhardt
Journal:  Blut       Date:  1984-07

8.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

9.  High-dose intravenous immunoglobulin for post-transfusion purpura.

Authors:  T Becker; S Panzer; D Maas; V Kiefel; R Sprenger; M Kirschbaum; C Mueller-Eckhardt
Journal:  Br J Haematol       Date:  1985-09       Impact factor: 6.998

10.  Murine monoclonal antibodies and human alloantisera specific for HLA inhibit monocyte phagocytosis of anti-D-sensitized human red blood cells.

Authors:  J Neppert; F Marquard; C Mueller-Eckhardt
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

View more
  3 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Modulation of functional activity of human polymorphonuclear and mononuclear phagocytes by intravenous gamma globulin.

Authors:  W Pruzanski; S Saito
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

3.  Impaired function of numerically augmented Fc-receptors on granulocytes in a HLA B8+ patient with palmoplantar pustulosis.

Authors:  R E Schopf; M Rehder; P Benes; K Bork; B Morsches
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.